233 related articles for article (PubMed ID: 37606566)
1. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
4. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer.
Xu Z; Chen Q; Shu L; Zhang C; Liu W; Wang P
Front Oncol; 2022; 12():970367. PubMed ID: 36003776
[TBL] [Abstract][Full Text] [Related]
6. M6A RNA Methylation Regulator HNRNPC Contributes to Tumorigenesis and Predicts Prognosis in Glioblastoma Multiforme.
Wang LC; Chen SH; Shen XL; Li DC; Liu HY; Ji YL; Li M; Yu K; Yang H; Chen JJ; Qin CZ; Luo MM; Lin QX; Lv QL
Front Oncol; 2020; 10():536875. PubMed ID: 33134160
[TBL] [Abstract][Full Text] [Related]
7. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
[TBL] [Abstract][Full Text] [Related]
9. m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer.
Zhao H; Xu Y; Xie Y; Zhang L; Gao M; Li S; Wang F
Front Cell Dev Biol; 2021; 9():650023. PubMed ID: 33748145
[TBL] [Abstract][Full Text] [Related]
10. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
11. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome.
Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y
Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909
[TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
Xu LC; Pan JX; Pan HD
Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
[TBL] [Abstract][Full Text] [Related]
13. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
Zhang T; Sheng P; Jiang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2805-2822. PubMed ID: 35780396
[TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
15. Prognostic and therapeutic implication of m6A methylation in Crohn disease.
He Y; Hu Y; Yuan M; Xu W; Du Y; Liu J
Medicine (Baltimore); 2022 Dec; 101(51):e32399. PubMed ID: 36595818
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ
Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.
Wang Y; Sun N; He R; Wang Z; Jin J; Gao T; Qu J
Clin Exp Med; 2024 May; 24(1):92. PubMed ID: 38693353
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma.
Liu T; Li C; Jin L; Li C; Wang L
Med Sci Monit; 2019 Dec; 25():9435-9445. PubMed ID: 31823961
[TBL] [Abstract][Full Text] [Related]
19. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of n6-methyladenosine (m6A) regulators and role of FTO/TNC in scleroderma.
Yu Y; Liang C; Tang Q; Shi Y; Shen L
Gene; 2024 Feb; 894():147989. PubMed ID: 37972699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
